Loading clinical trials...
Loading clinical trials...
An Open- Label, Dose Escalation Study to Assess the Safety, Pharmacokinetics and Pharmacodynamic Signals of DUR-928 in Patients With Alcoholic Hepatitis
Conditions
Interventions
DUR-928 30 mg
DUR-928 90 mg
+1 more
Locations
7
United States
DURECT Study Site 0001
San Diego, California, United States
DURECT Study Site 007
Miami, Florida, United States
DURECT Study Site 0004
Atlanta, Georgia, United States
DURECT Study Site 0002
Chicago, Illinois, United States
DURECT Study Site 008
Indianapolis, Indiana, United States
DURECT Study Site 0005
Louisville, Kentucky, United States
Start Date
April 18, 2018
Primary Completion Date
September 9, 2019
Completion Date
September 9, 2019
Last Updated
September 24, 2024
NCT04088370
NCT06159244
NCT06919458
NCT02344680
NCT06285253
NCT03149627
Lead Sponsor
Durect
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions